Hyponatremia News and Research

RSS

Hyponatremia refers to an abnormally low level of the electrolyte sodium (salt) in the blood. Sodium is an electrolyte that helps regulate the amount of water within and around cells in the body.

Plant-based diets trigger remission in Sjögren's syndrome and lupus cases

Three case studies show women with autoimmune diseases achieving symptom remission through plant-based diets, suggesting potential for dietary interventions in chronic disease management.

28 Feb 2024

Chronic underhydration linked to major health risks, study finds

Chronic underhydration has been linked to severe long-term health issues, including heart disease, diabetes, and kidney dysfunction, underscoring the need for increased hydration awareness and intervention strategies.

27 Feb 2024

The long-term effects of SARS-CoV-2 infection on T cell activation: autoimmune disorders and endothelial cell dysfunction

Authors explored the impact of SARS-CoV-2 on thymus (T) cell activation.

1 Aug 2023

A scientific statement from the American Heart and Stroke Association on the prevalence, diagnosis, and management of poststroke cognitive impairment

Researchers reviewed the incidence, prevalence, diagnosis, and management of post-stroke cognitive impairment.

3 May 2023

The impact of viral infections on the human endocrine system

Researchers briefly outlined how viral infections trigger endocrinopathies in humans.

3 Feb 2023

Chinese study determines the real-world effectiveness of COVID-19 vaccines

A recent study aimed to determine the real-world effectiveness of COVID-19 vaccines against SARS-CoV-2 infection.

14 Oct 2022

Two cases of MIS-C after laboratory-confirmed SARS-CoV-2 breakthrough infections in fully vaccinated adolescent patients

Researchers investigated whether COVID-19 vaccination effectively protected adolescents in the United States from multisystem inflammatory syndrome (MIS).

2 Jun 2022

Researchers evaluate atovaquone as a COVID-19 treatment

Researchers evaluated a drug, atovaquone, for COVID-19 treatment.

30 May 2022

Study assesses the effect of extreme heat on workforce health

Working outdoors during periods of extreme heat can cause discomfort, heat stress, or heat illnesses – all growing concerns for people who live and work in Southwestern cities like Las Vegas, where summer temperatures creep higher each year.

11 May 2022

Rising global temperatures likely to increase the health burden from hyponatremia

Global warming is likely to increase the number of people requiring hospitalization due to critically low sodium levels in the blood, a condition known as hyponatremia.

8 Mar 2022

Novel diarylamides show promise as orally active diuretics to treat hyponatremia

Urea transporters (UT) play a vital role in the mechanism of urine concentration and are recognized as novel targets for the development of salt-sparing diuretics. Thus, UT inhibitors are promising for development as novel diuretics.

8 Apr 2021

Targeted therapy achieves durable objective responses Phase I/II LIBRETTO-001 trial

For patients with non-small cell lung cancers (NSCLC) marked by RET gene fusions, the targeted therapy selpercatinib was well tolerated and achieved durable objective responses, or tumor shrinkage, in the majority of participants in the Phase I/II LIBRETTO-001 trial, according to researchers from The University of Texas MD Anderson Cancer Center.

27 Aug 2020

Kawasaki disease outbreak in children with COVID-19

The ongoing COVID-19 pandemic has marched its way to almost all parts of the world, with hundreds of thousands of deaths and over 4.5 million cases as of May 15, 2020. One saving grace has been the apparent sparing of children, though the mortality in older people is quite high.

17 May 2020

Individuals should to 'drink to thirst' to manage exercise-related hyponatremia

Hyponatremia is a condition of low sodium concentration in the blood. Prolonged overhydration during exercise is the primary cause of all forms of exercise-associated hyponatremia (EAH) and should be avoided.

18 Mar 2020

Guideline-recommended diuretic linked to more side effects than similar antihypertensive drug

Chlorthalidone, the guideline-recommended diuretic for lowering blood pressure, causes more serious side effects than hydrochlorothiazide, a similarly effective diuretic, according to a new study led by researchers at Columbia University Irving Medical Center.

17 Feb 2020

Tanner Pharma Group signs distribution agreement with Nephcentric LLC

Tanner Pharma Group, a global provider of integrated specialty access solutions, has announced the signing of a distribution agreement with Nephcentric LLC, a developer and marketer of evidence based therapeutic options for people with kidney disease and metabolic disorders.

From Tanner Pharma Group 29 Aug 2019

$FDA grants accelerated approval to new treatment for refractory multiple myeloma$

FDA grants accelerated approval to new treatment for refractory multiple myeloma

Today, the U.S. Food and Drug Administration granted accelerated approval to Xpovio (selinexor) tablets in combination with the corticosteroid dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma who have received at least four prior therapies and whose disease is resistant to several other forms of treatment, including at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

3 Jul 2019

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

Hyponatremia News and Research

Further Reading

Plant-based diets trigger remission in Sjögren's syndrome and lupus cases

Chronic underhydration linked to major health risks, study finds

The long-term effects of SARS-CoV-2 infection on T cell activation: autoimmune disorders and endothelial cell dysfunction

A scientific statement from the American Heart and Stroke Association on the prevalence, diagnosis, and management of poststroke cognitive impairment

The impact of viral infections on the human endocrine system

Chinese study determines the real-world effectiveness of COVID-19 vaccines

Two cases of MIS-C after laboratory-confirmed SARS-CoV-2 breakthrough infections in fully vaccinated adolescent patients

Researchers evaluate atovaquone as a COVID-19 treatment

Study assesses the effect of extreme heat on workforce health

Rising global temperatures likely to increase the health burden from hyponatremia

Novel diarylamides show promise as orally active diuretics to treat hyponatremia

Targeted therapy achieves durable objective responses Phase I/II LIBRETTO-001 trial

Kawasaki disease outbreak in children with COVID-19

Individuals should to 'drink to thirst' to manage exercise-related hyponatremia

Guideline-recommended diuretic linked to more side effects than similar antihypertensive drug

Tanner Pharma Group signs distribution agreement with Nephcentric LLC

FDA grants accelerated approval to new treatment for refractory multiple myeloma

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News